Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies

We performed two phase I trials of the histone deacetylase inhibitor vorinostat combined with either the vascular endothelial growth factor inhibitor pazopanib (NCT01339871) or the proteasome inhibitor ixazomib (NCT02042989) in patients with metastatic TP53 mutant solid tumors. Both trials followed...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Sci Rep
Hlavní autoři: Wang, Yudong, Janku, Filip, Piha-Paul, Sarina, Hess, Kenneth, Broaddus, Russell, Liu, Lidong, Shi, Naiyi, Overman, Michael, Kopetz, Scott, Subbiah, Vivek, Naing, Aung, Hong, David, Tsimberidou, Apostolia M., Karp, Daniel, Yao, James, Fu, Siqing
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7033174/
https://ncbi.nlm.nih.gov/pubmed/32080210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-58366-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky